Guggenheim analyst Michael Schmidt downgraded ImmunoGen (IMGN) to Neutral from Buy with a price target of $31, up from $25, after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN: